| Regulation of Nuclear Factor-KappaB (NF-κB) signaling pathway by non-coding RNAs in cancer: Inhibiting or promoting carcinogenesis? S Mirzaei, A Zarrabi, F Hashemi, A Zabolian, H Saleki, A Ranjbar, ... Cancer Letters 509, 63-80, 2021 | 209 | 2021 |
| Curcumin and its derivatives in cancer therapy: Potentiating antitumor activity of cisplatin and reducing side effects AJ Abadi, S Mirzaei, MK Mahabady, F Hashemi, A Zabolian, F Hashemi, ... Phytotherapy Research 36 (1), 189-213, 2022 | 164 | 2022 |
| New insight towards development of paclitaxel and docetaxel resistance in cancer cells: EMT as a novel molecular mechanism and therapeutic possibilities M Ashrafizadeh, S Mirzaei, F Hashemi, A Zarrabi, A Zabolian, H Saleki, ... Biomedicine & Pharmacotherapy 141, 111824, 2021 | 163 | 2021 |
| NF‐κB as a regulator of cancer metastasis and therapy response: A focus on epithelial–mesenchymal transition S Mirzaei, S Saghari, F Bassiri, R Raesi, A Zarrabi, K Hushmandi, G Sethi, ... Journal of cellular physiology 237 (7), 2770-2795, 2022 | 156 | 2022 |
| Nrf2 signaling pathway in cisplatin chemotherapy: Potential involvement in organ protection and chemoresistance S Mirzaei, AT Mohammadi, MH Gholami, F Hashemi, A Zarrabi, ... Pharmacological research 167, 105575, 2021 | 153 | 2021 |
| Caffeic acid and its derivatives as potential modulators of oncogenic molecular pathways: New hope in the fight against cancer S Mirzaei, MH Gholami, A Zabolian, H Saleki, MV Farahani, S Hamzehlou, ... Pharmacological research 171, 105759, 2021 | 150 | 2021 |
| The long and short non-coding RNAs modulating EZH2 signaling in cancer S Mirzaei, MH Gholami, K Hushmandi, F Hashemi, A Zabolian, I Canadas, ... Journal of Hematology & Oncology 15 (1), 18, 2022 | 147 | 2022 |
| Advances in understanding the role of P-gp in doxorubicin resistance: Molecular pathways, therapeutic strategies, and prospects S Mirzaei, MH Gholami, F Hashemi, A Zabolian, MV Farahani, ... Drug Discovery Today 27 (2), 436-455, 2022 | 138 | 2022 |
| Molecular landscape of LncRNAs in prostate cancer: a focus on pathways and therapeutic targets for intervention S Mirzaei, MDA Paskeh, E Okina, MH Gholami, K Hushmandi, M Hashemi, ... Journal of Experimental & Clinical Cancer Research 41 (1), 214, 2022 | 126 | 2022 |
| AIE-featured tetraphenylethylene nanoarchitectures in biomedical application: Bioimaging, drug delivery and disease treatment KSS Kumar, YR Girish, M Ashrafizadeh, S Mirzaei, KP Rakesh, ... Coordination Chemistry Reviews 447, 214135, 2021 | 109 | 2021 |
| Elucidating role of reactive oxygen species (ROS) in cisplatin chemotherapy: a focus on molecular pathways and possible therapeutic strategies S Mirzaei, K Hushmandi, A Zabolian, H Saleki, SMR Torabi, A Ranjbar, ... Molecules 26 (8), 2382, 2021 | 102 | 2021 |
| (Nano) platforms in bladder cancer therapy: Challenges and opportunities M Ashrafizadeh, A Zarrabi, H Karimi‐Maleh, A Taheriazam, S Mirzaei, ... Bioengineering & translational medicine 8 (1), e10353, 2023 | 99 | 2023 |
| Nrf2 signaling pathway in chemoprotection and doxorubicin resistance: potential application in drug discovery S Mirzaei, A Zarrabi, F Hashemi, A Zabolian, H Saleki, N Azami, ... Antioxidants 10 (3), 349, 2021 | 97 | 2021 |
| Gallic acid for cancer therapy: Molecular mechanisms and boosting efficacy by nanoscopical delivery M Ashrafizadeh, A Zarrabi, S Mirzaei, F Hashemi, S Samarghandian, ... Food and Chemical Toxicology 157, 112576, 2021 | 93 | 2021 |
| Wnt/β-catenin signaling as a driver of hepatocellular carcinoma progression: an emphasis on molecular pathways M Deldar Abad Paskeh, S Mirzaei, M Ashrafizadeh, A Zarrabi, G Sethi Journal of Hepatocellular Carcinoma, 1415-1444, 2021 | 92 | 2021 |
| Small interfering RNA (siRNA) to target genes and molecular pathways in glioblastoma therapy: Current status with an emphasis on delivery systems S Mirzaei, MK Mahabady, A Zabolian, A Abbaspour, P Fallahzadeh, ... Life Sciences 275, 119368, 2021 | 91 | 2021 |
| Employing siRNA tool and its delivery platforms in suppressing cisplatin resistance: approaching to a new era of cancer chemotherapy S Mirzaei, MH Gholami, F Hashemi, A Zabolian, K Hushmandi, ... Life Sciences 277, 119430, 2021 | 84 | 2021 |
| Flavonoids targeting HIF-1: Implications on cancer metabolism M Samec, A Liskova, L Koklesova, S Mersakova, J Strnadel, K Kajo, ... Cancers 13 (1), 130, 2021 | 82 | 2021 |
| An evaluation on potential anti-oxidant and anti-inflammatory effects of Crocin S Bastani, V Vahedian, M Rashidi, A Mir, S Mirzaei, I Alipourfard, ... Biomedicine & Pharmacotherapy 153, 113297, 2022 | 67 | 2022 |
| Doxorubicin-loaded graphene oxide nanocomposites in cancer medicine: stimuli-responsive carriers, co-delivery and suppressing resistance M Ashrafizadeh, H Saebfar, MH Gholami, K Hushmandi, A Zabolian, ... Expert opinion on drug delivery 19 (4), 355-382, 2022 | 66 | 2022 |